Skip to main content

Featured Studies

Office of Patient Recruitment

This web page makes it easy to search for featured research studies at the NIH Clinical Center. You can search for specific studies by entering keywords related to your symptoms in the search box or by using the sort and filter options.


To view a full list of all studies conducted at the NIH Clinical Center, visit Search the Studies.

Filter By

Visit Type

Patient or Healthy Volunteer

Age Group

Institution

Web Page Language

Reset All Filters
30 results
Men at High Genetic Risk for Prostate Cancer

Men at High Genetic Risk for Prostate Cancer

Join a National Institutes of Health (NIH) research study seeking mean men who have a genetic risk factor for developing prostate cancer. Researchers want to follow the prostate health of men who have specific genetic changes associated with prostate cancer to help them learn more about which men are at higher risk for prostate cancer.
Learn More
If you have questions or would like to learn more about this study, contact 800-411-1222 and refer to study 19-C-0040.
A Phase II Study of Combined Treatment of Durvalumab, Bevacizuamab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects with Hepatocellular Carcinoma (HCC)or Biliary Tract Carcinoma (BTC)

A Phase II Study of Combined Treatment of Durvalumab, Bevacizuamab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects with Hepatocellular Carcinoma (HCC)or Biliary Tract Carcinoma (BTC)

Hepatocellular Carcinoma (HCC) is the fifth most common cancer in the world. Patients with advanced HCC survive an average of 6 to 9 months. Researchers at the National Institutes of Health are testing the use of an immunotherapy medication called durvalumab, with two other chemotherapy medications, doxorubicin-eluting beads and bevacizumab. This clinical research study will investigate if this combination of medications can stop the progression of HCC.
Learn More
If you have questions or would like to learn more about this study, contact 800-411-1222 and refer to study 19-C-0094.
Phase II Trial Evaluating Nivolumab in Patients with IDH-Mutant Gliomas with and without Hypermutator Phenotype

Phase II Trial Evaluating Nivolumab in Patients with IDH-Mutant Gliomas with and without Hypermutator Phenotype

National Cancer Institute (NCI) researchers are conducting a study of patients with IDH-mutated gliomas. This study will test whether stimulating the immune system using the drug nivolumab can shrink recurrent IDH-mutant gliomas with and without hypermutator phenotype or increase the time it takes for them to grow or spread.

Learn More
If you have questions or would like to learn more about this study, contact 800-411-1222 and refer to study 19-C-0006.
Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients with Recurrent Select Rare CNS Cancers

Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients with Recurrent Select Rare CNS Cancers

National Cancer Institute (NCI) researchers are conducting a study of patients with rare central nervous system (CNS) tumors. More than 130 primary rare CNS (brain or spine) tumors have been identified. Most affect less than 2,000 people in the United States each year. This study will test whether stimulating the immune system using the drug nivolumab can shrink select rare brain or spine tumors or increase the time it takes for them to grow or spread.

Learn More
If you have questions or would like to learn more about this study, contact 800-411-1222 and refer to study 17-C-0102.
The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment with Beta-3-Adrenergic Receptor Agonists

The Physiological Responses and Adaptation of Brown Adipose Tissue to Chronic Treatment with Beta-3-Adrenergic Receptor Agonists

Women diagnosed with polycystic ovary syndrome (PCOS) needed for a research study at the National Institutes of Health (NIH). Researchers want to learn more about how a medication may be used to help your body's insulin work better and if this can improve your overall metabolic health.
Learn More
If you have questions or would like to learn more about this study, contact 800-411-1222 and refer to study 17-DK-0054.
Energy Expenditure Responses to Different Temperatures

Energy Expenditure Responses to Different Temperatures

Researchers at the National Institutes of Health (NIH) Clinical Center seek healthy women to participate in a research study. Doctors want to learn how the body burns energy at different temperatures. Compensation is provided.
Learn More
If you have questions or would like to learn more about this study, contact 800-411-1222 and refer to study 12-DK-0097.
Was this page helpful?